Payment overview · 2025
General Payments
$181.42
5 reported records · 5 companies
Healthcare provider profile · identity verified
Neelima Ryali, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ABILENE, TX · NPI 1508874918
Verified facts
What the public records show
CMS Open Payments records show Neelima Ryali, M.D. received $181.42 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 54.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $98.02 | 54.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $26.72 | 14.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.26 | 10.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.73 | 10.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.69 | 10.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $181.42 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $98.02 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $26.72 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 478 | 154 |
| Levothyroxine Sodium | Levothyroxine Sodium | 404 | 135 |
| Gabapentin | Gabapentin | 375 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 370 | 126 |
| Omeprazole | Omeprazole | 320 | 98 |
| Lisinopril | Lisinopril | 282 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 91 |
| Furosemide | Furosemide | 248 | 82 |
| Metformin Hcl | Metformin Hcl | 239 | 75 |
| Montelukast Sodium | Montelukast Sodium | 238 | 62 |
| Potassium Chloride | Potassium Chloride | 212 | 65 |
| Alprazolam | Alprazolam | 208 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 52 |
| Losartan Potassium | Losartan Potassium | 192 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 46 |
| Simvastatin | Simvastatin | 162 | 48 |
| Alendronate Sodium | Alendronate Sodium | 160 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 60 |
| Trazodone Hcl | Trazodone Hcl | 148 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 51 |
| Tramadol Hcl | Tramadol Hcl | 131 | 56 |
| Allopurinol | Allopurinol | 129 | 33 |
| Sertraline Hcl | Sertraline Hcl | 126 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 38 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 118 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 112 | 25 |
| Methocarbamol | Methocarbamol | 104 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 37 |
| Meloxicam | Meloxicam | 94 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 29 |
| Ozempic | Semaglutide | 89 | 22 |
| Carvedilol | Carvedilol | 84 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 27 |
| Eliquis | Apixaban | 75 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 19 |
| Spironolactone | Spironolactone | 70 | 20 |
| Bupropion Xl | Bupropion Hcl | 68 | 19 |
| Metformin Hcl Er | Metformin Hcl | 66 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 18 |
| Ezetimibe | Ezetimibe | 63 | 21 |
| Januvia | Sitagliptin Phosphate | 63 | 14 |
| Donepezil Hcl | Donepezil Hcl | 61 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 14 |
| Prednisone | Prednisone | 58 | 46 |
| Pregabalin | Pregabalin | 58 | 11 |
| Atenolol | Atenolol | 57 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 18 |
| Jardiance | Empagliflozin | 52 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 20 |
| Cefuroxime | Cefuroxime Axetil | 47 | 41 |
| Mounjaro | Tirzepatide | 47 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 15 |
| Bupropion Hcl | Bupropion Hcl | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | 14 |
| Trulicity | Dulaglutide | 42 | 13 |
| Celecoxib | Celecoxib | 41 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 15 |
| Memantine Hcl | Memantine Hcl | 41 | 12 |
| Ondansetron Odt | Ondansetron | 41 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 13 |
| Farxiga | Dapagliflozin Propanediol | 40 | 13 |
| Glipizide | Glipizide | 40 | suppressed |
| Finasteride | Finasteride | 39 | 15 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Tradjenta | Linagliptin | 39 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 15 |
| Meclizine Hcl | Meclizine Hcl | 38 | suppressed |
| Temazepam | Temazepam | 38 | 14 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 34 |
| Fluconazole | Fluconazole | 34 | 25 |
| Famotidine | Famotidine | 33 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 13 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 12 |
| Levofloxacin | Levofloxacin | 26 | 25 |
| Nystatin | Nystatin | 26 | 14 |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | 11 |
| Estradiol | Estradiol | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 11 |
| Estazolam | Estazolam | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Mitigare | Colchicine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181.42 · 5 records | Amgen Inc. | BREZTRI, GEMTESA, LEQEMBI, LEQVIO, UPLIZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error